Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Obsessive-Compulsive Disorder
Interventions: Troriluzole, Placebo; Drug
Lead sponsor: Biohaven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 73
States / cities: Chandler, Arizona • Phoenix, Arizona • Bellflower, California + 62 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 1,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more

Conditions: Healthy
Interventions: Fish Oil, Safflower Oil, Ethanol, Omega-3 polyunsaturated fatty acids, Omega-6 polyunsaturated fatty acid; Drug · Dietary Supplement
Lead sponsor: Carsten Skarke, MD; Other
Eligibility: 21 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Participants
Interventions: E2730, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Urinary Tract Infections
Interventions: D-Mannose; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 20 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Irritable Bowel Syndrome
Interventions: curcumin, placebo; Dietary Supplement
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Tourette Syndrome
Interventions: Valbenazine, Placebo oral capsule; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 48
States / cities: Sun City, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 43 more

Conditions: Post Traumatic Stress Disorder
Interventions: TSND-201, Placebo; Drug
Lead sponsor: Transcend Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Denver, Colorado • Bradenton, Florida • Orlando, Florida + 5 more

Conditions: Arthralgia, Bunion, Hallux Valgus, Pain
Interventions: Tapentadol (CG5503), oxycodone, placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 7
States / cities: Glendale, California • Pasadena, Maryland • Austin, Texas + 4 more

Conditions: Systemic Lupus Erythematosus
Interventions: GLPG3667, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Tucson, Arizona • La Jolla, California • Rancho Mirage, California + 16 more

Conditions: Trichotillomania (Hair-Pulling Disorder)
Interventions: Valbenazine Oral Capsule, Placebo Oral capsule; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: COVID-19, Lung Infection
Interventions: Opaganib, Placebo; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Type 1 Diabetes
Interventions: Formoterol, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Fragile X Syndrome, FXS, Fra(X) Syndrome
Interventions: BPN14770, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Enteric Hyperoxaluria
Interventions: ALLN-177, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Endometriosis
Interventions: 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule; Drug
Lead sponsor: Kissei Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 107
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more

Conditions: Depression
Interventions: NSI-189 Phosphate, microcrystalline cellulose capsules; Drug
Lead sponsor: Neuralstem Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Glioblastoma
Interventions: Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine; Drug · Radiation · Biological
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years and older
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more

Conditions: Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Interventions: RBS2418, Placebo; Drug
Lead sponsor: Riboscience, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Newark, Delaware • Las Vegas, Nevada • Nashville, Tennessee + 1 more

Conditions: Hypertension
Interventions: grape seed extract, grape seed extract placebo; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure, atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Metabolic Health, Weight Loss, Stress, Well-Being, Psychological, Sleep, Healthy Eating
Interventions: Slimbiotics Postbiotic, Placebo; Other
Lead sponsor: Slimbiotics; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157 or Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Diabetic Neuropathy, Painful
Interventions: PF-05089771 150 mg, Matched placebo for PF-05089771 150 mg and pregabalin 300 mg, Pregabalin 300 mg, PF-05089771 150 mg + Pregabalin 300 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 32
States / cities: Phoenix, Arizona • Fresno, California • Bradenton, Florida + 24 more

Search by objective public record fields.

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants

Nutraceutical Efficacy for rUTI

Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial

Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension

Vascular Improvement With Olmesartan Medoxomil Study

A Study to Evaluate the Effect of SlimBiotics L. Fermentum K8 Postbiotic on Weight Management and Metabolic Health Outcomes

A Study Of PF-05175157 In Healthy Volunteers

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)